Literature DB >> 22027905

Comment on "tissue factor-dependent chemokine production aggravates experimental colitis".

Julia E Gambone, A Phillip Owens, Nigel Mackman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22027905      PMCID： PMC3321812          DOI： 10.2119/molmed.2011.00303

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  5 in total

1.  Tissue factor-dependent chemokine production aggravates experimental colitis.

Authors:  Karla C S Queiroz; Cornelis Van 't Veer; Yascha Van Den Berg; Janwillem Duitman; Henri H Versteeg; Hella L Aberson; Angelique P Groot; Marleen I Verstege; Joris J T H Roelofs; Anje A Te Velde; C Arnold Spek
Journal:  Mol Med       Date:  2011-06-22       Impact factor: 6.354

2.  Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction.

Authors:  R Pawlinski; A Fernandes; B Kehrle; B Pedersen; G Parry; J Erlich; R Pyo; D Gutstein; J Zhang; F Castellino; E Melis; P Carmeliet; G Baretton; T Luther; M Taubman; E Rosen; N Mackman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Low levels of tissue factor are compatible with development and hemostasis in mice.

Authors:  G C Parry; J H Erlich; P Carmeliet; T Luther; N Mackman
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

4.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.

Authors:  Kathryn J Moore; Vidya V Kunjathoor; Stephanie L Koehn; Jennifer J Manning; Anita A Tseng; Jessica M Silver; Mary McKee; Mason W Freeman
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

5.  Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe.

Authors:  Catherine A Reardon; Lydia Blachowicz; John Lukens; Michael Nissenbaum; Godfrey S Getz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-05       Impact factor: 8.311
  5 in total
  1 in total

1.  Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.

Authors:  Janine Koepke; Marc Dresel; Severin Schmid; Timm Greulich; Björn Beutel; Bernd Schmeck; Claus Franz Vogelmeier; Sabina Janciauskiene; Andreas Rembert Koczulla
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.